A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs)

NCT05905458 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis B

Interventions

DRUG: HRS9950 tablets
DRUG: HRS9950 tablets
DRUG: HRS9950 placebo tablets

Sponsor

Chengdu Suncadia Medicine Co., Ltd.